Active Biotech: Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Hu...
September 13 2018 - 5:00AM
PRESS RELEASE
Data from the Phase 2
LEGATO-HD study of laquinimod in Huntington's disease will be
presented at the scientific conference "European Huntington's
Disease Network (EHDN) plenary meeting 2018"
Lund Sweden,
September 13, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI)
announces that initial data from the Phase 2 LEGATO-HD study of
laquinimod in Huntington's disease will be presented by Global
Coordinating Principal Investigator, Dr Ralf Railmann at the
scientific conference "European Huntington's Disease Network (EHDN)
plenary meeting 2018" held September 14-16 in Vienna. The results
will be presented at an oral session on September 16 and as a
poster titled "LEGATO-HD Study: A phase 2 study assessing the
efficacy and safety of laquinimod as a treatment for Huntington
disease". Data presented includes results on primary and secondary
endpoints and safety profile. Full analysis of the study is ongoing
and further results will be presented at upcoming scientific
meetings.
The poster will be available on Active Biotech's website
(www.activebiotech.com) in connection with the presentation.
ABOUT LEGATO-HD
LEGATO-HD is a multinational, multicenter, randomized,
double-blind, placebo-controlled, parallel-group Phase 2 study of
laquinimod as a potential treatment in patients with HD. The study
was designed to evaluate three doses arms (0.5mg, 1.0mg, and 1.5mg
daily) versus placebo. The highest dose of 1.5 mg was discontinued
in January 2016 as a precautionary measure after cardiovascular
safety problems were observed in multiple sclerosis studies with
laquinimod of 1.2 mg and 1.5 mg respectively. No similar issues
were identified in the LEGATO-HD study.
The primary endpoint evaluating the change from
baseline at month 12 in the UHDRS-TMS for the 1.0 mg dose as
compared with placebo was not achieved. The secondary endpoint,
percent change in brain atrophy (caudate volume) from baseline at
12 months in the 1.0 mg dose as compared to placebo, was met. The
safety profile in the study was similar to that expected in the
patient population.
Full analysis of the study is ongoing and the
exploratory outcome includes change of Unified Huntington's Disease
Rating Scale - Total Motor Score (UHDRS-TMS) and percentage change
in brain atrophy for the 0.5 mg dose, as well as changes in
measured motor function, cognitive function, functional capacity
and brain volumes for the 1.0 and 0.5 mg doses individually. The
safety measures included adverse event reporting, clinical
laboratory tests, vital signs, electrocardiograms, physical
examinations and suicidality.
The study was conducted by Teva in collaboration
with the Huntington Study Group and European Huntington's Disease
Network. The study is registered as NCT02215616 on
clinicaltrials.gov and its EudraCT number is
2014-000418-75.
Lund September 13, 2018
Active Biotech AB (publ)
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Email: hans.kolam@activebiotech.com
Helén Tuvesson, CEO
Tel +46 46 19 21 56
Email: helen.tuvesson@activebiotech.com
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties in development for neurodegenerative diseases. ANYARA,
an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit http://www.activebiotech.com/en for more
information.
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tfn +46 46 19 20 00
The information
was submitted for publication at 11.00
a.m. CET on September 13, 2018.
Presentation of LegatoHD at
EHDN
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024